- Home
- ORGO vs MYGN Comparison
ORGO vs MYGN Comparison
Compare ORGO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORGO | MYGN |
|---|---|---|
| Founded | 1985 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.4M | 625.5M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | ORGO | MYGN |
|---|---|---|
| Price | $4.80 | $7.01 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $8.00 | ★ $11.82 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 11-06-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $465,218,000.00 | ★ $825,300,000.00 |
| Revenue This Year | $8.14 | $0.10 |
| Revenue Next Year | $6.33 | $5.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.24 | 0.21 |
| 52 Week Low | $2.61 | $3.76 |
| 52 Week High | $7.08 | $15.47 |
Technical Indicators
Market Signals| Indicator | ORGO | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 46.64 |
| Support Level | $4.66 | $7.15 |
| Resistance Level | $5.83 | $7.43 |
| Average True Range (ATR) | 0.20 | 0.30 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 18.13 | 11.44 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.